CD274 and non-small cell lung carcinoma: In the phase III EMPOWER-Lung 1 trial, single-agent cemiplimab has shown superior efficacy and improved overall survival (OS) compared to chemotherapy in patients with advanced NSCLC and high PD-L1 expression.